Immune-Boosting cocktail aims to tackle Hard-to-Treat breast cancer

NCT ID NCT05029999

Recruiting now Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal is to find the best dose and see how the combination affects the immune system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pegylated liposomal doxorubicin (PLD), CDX-1140 (CD40 agonist), and CDX-301 (Flt3 ligand)
What this could lead to: If successful, this combination could offer a new treatment option for people with metastatic HER2-negative breast cancer by boosting the immune system to fight the cancer.
What could go wrong: This is an early-phase trial with only 30 participants, so the benefits are uncertain. The drug combination may cause serious side effects, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-NEGATIVE BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Show contact details

Locations

Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States

Contact Email: •••••@•••••
Sarah Cannon Research Institute
WITHDRAWN

Nashville, Tennessee, 37203, United States
Texas Oncology, P.A.
ACTIVE_NOT_RECRUITING

Dallas, Texas, 75251, United States
The University of Texas Health Science Center at San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Chicago Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.